This study is looking into a medication called JZP926 capsule for people with Juvenile Myoclonic Epilepsy (JME). JME is a type of epilepsy that causes sudden, brief muscle jerks, often in the morning. Researchers want to see how safe and effective JZP926 capsule is compared to a placebo (an inactive substance) in reducing the number of days you experience these myoclonic seizures. You might be able to join if you are at least 10 years old, have a diagnosis of JME, and have at least 4 myoclonic seizure days per 28 days. The study aims to measure how much JZP926 capsule changes your myoclonic seizure days over 16 weeks. The current status of this study is unclear, and it plans to enroll 260 participants.

Study design

This is a Phase 2/3, multi-center study where participants will be randomly assigned to receive either JZP926 capsule or a placebo. Neither you nor your doctor will know which treatment you are receiving (double-blind).

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured up to the end of a 16-week treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.